Virtu Financial’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Virtu Financial’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,276	Closed	-$16K	–	2280
2024 Q3	$16K	Buy	+12,276	New	+$59.3K	﹤0.01%	1153
2022 Q3	–	Sell	-2,176	Closed	-$48K	–	2395
2022 Q2	$48K	Buy	+2,176	New	+$48.5K	﹤0.01%	1133
2022 Q1	–	Sell	-1,988	Closed	-$90K	–	2248
2021 Q4	$90K	Buy	1,988 +798	+67%	+$53.7K	0.01%	1174
2021 Q3	$99K	Buy	+1,190	New	+$98.4K	0.01%	1155
2019 Q2	–	Sell	-79	Closed	-$13K	–	1968
2019 Q1	$13K	Sell	79 -401	-84%	-$59.8K	﹤0.01%	1323
2018 Q4	$52K	Buy	+480	New	+$96K	﹤0.01%	1262

Other funds holding ONCT

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Virtu Financial's ONCT Position: Q4 2024 in Review

Virtu Financial sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 12,276 shares — an estimated $16K sold.

Virtu Financial first reported a position in ONCT in Q4 2018 and held it in 6 quarters. The position peaked at $99K in Q3 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

Virtu Financial reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Virtu Financial sold 12,276 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $16K.
Virtu Financial first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
Virtu Financial's Oncternal Therapeutics, Inc. Common Stock position peaked at $99K in Q3 2021.
4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Virtu Financial's 13F filing for Q4 2024, filed 11 Feb 2025.